A novel covalent approach to bio-conjugate silver coated single walled carbon nanotubes with antimicrobial peptide

Chaudhari, Atul A.; Ashmore, D’andrea; Nath, Subrata Deb; Kate, Kunal H.; Dennis, Vida A.; Singh, Shree R.; Owen, Don R.; Palazzo, Chris; Arnold, Robert D.; Miller, Michael E.; Pillai, Shreekumar R.

doi:10.1186/s12951-016-0211-z

Cited by 48 publications

(29 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mRNA expression levels of E. coli genes associated with the citric acid (TCA) Cycle, amino acid metabolism, virulence, DNA repair and transcription were evaluated using qRT-PCR 25 , 26 . The primers used to amplify each gene and their origins are indicated in Table 1 27 – 40 .…”

Section: Methodsmentioning

confidence: 99%

Evaluation of E. coli inhibition by plain and polymer-coated silver nanoparticles

Ashmore

Chaudhari

Barlow

et al. 2018

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

Escherichia coli causes various ailments such as septicemia, enteritis, foodborne illnesses, and urinary tract infections which are of concern in the public health field due to antibiotic resistance. Silver nanoparticles (AgNP) are known for their biocompatibility and antibacterial activity, and may prove to be an alternative method of treatment, especially as wound dressings. In this study, we compared the antibacterial efficacy of two polymer-coated silver nanoparticles either containing 10% Ag (Ag 10% + Polymer), or 99% Ag (AgPVP) in relation to plain uncoated silver nanoparticles (AgNP). Atomic force microscopy was used to characterize the nanoparticles, and their antibacterial efficacy was compared by the minimum inhibitory concentration (MIC) and bacterial growth curve assays, followed by molecular studies using scanning electron microscopy (SEM) and (qRT- PCR). AgNP inhibited the growth of E. coli only at 0.621 mg/mL, which was double the concentration required for both coated nanoparticles (0.312 mg/mL). Similarly, bacterial growth was impeded as early as 8 h at 0.156 mg/mL of both coated nanoparticles as compared to 0.312 mg/mL for plain AgNP. SEM data showed that nanoparticles damaged the cell membrane, resulting in bacterial cell lysis, expulsion of cellular contents, and complete disintegration of some cells. The expression of genes associated with the TCA cycle (aceF and frdB) and amino acid metabolism (gadB, metL, argC) were substantially downregulated in E. coli treated with nanoparticles. The reduction in the silver ion (Ag+) concentration of polymer-coated AgNP did not affect their antibacterial efficacy against E. coli.

show abstract

Section: Methodsmentioning

confidence: 99%

Evaluation of E. coli inhibition by plain and polymer-coated silver nanoparticles

Ashmore

Chaudhari

Barlow

et al. 2018

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

show abstract

“…Many inorganic materials such as mesoporous silica particles [ 149 ], titanium [ 150 ], metal nanoparticles (mostly Au [ 151 ] and Ag [ 152 ]), quantum dots [ 153 ], graphene [ 154 ] and carbon nanotubes [ 155 ] have been utilized for AMP delivery systems. Mesoporous nanoparticles can be obtained from various materials, but silica nanoparticles have been used extensively due to their ability to form well defined pores for the loading of AMPs [ 156 ].…”

Section: Strategies To Improve Antimicrobial Peptidesmentioning

confidence: 99%

Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo

2018

View full text Add to dashboard Cite

Antibiotic resistance is projected as one of the greatest threats to human health in the future and hence alternatives are being explored to combat resistance. Antimicrobial peptides (AMPs) have shown great promise, because use of AMPs leads bacteria to develop no or low resistance. In this review, we discuss the diversity, history and the various mechanisms of action of AMPs. Although many AMPs have reached clinical trials, to date not many have been approved by the US Food and Drug Administration (FDA) due to issues with toxicity, protease cleavage and short half-life. Some of the recent strategies developed to improve the activity and biocompatibility of AMPs, such as chemical modifications and the use of delivery systems, are also reviewed in this article.

show abstract

“…Future clinical studies of these hydrogels and other delivery technologies will determine their safety and efficiency. Additional drug delivery strategies include carbon nanotubes and magnetic nanoparticles (López-Abarrategui et al, 2013;Chaudhari et al, 2016).…”

Section: Delivery and Formulationsmentioning

confidence: 99%

Antifungal Peptides as Therapeutic Agents

Ullivarri

Arbulu

García-Gutiérrez

et al. 2020

Front. Cell. Infect. Microbiol.

175

132

View full text Add to dashboard Cite

Fungi have been used since ancient times in food and beverage-making processes and, more recently, have been harnessed for the production of antibiotics and in processes of relevance to the bioeconomy. Moreover, they are starting to gain attention as a key component of the human microbiome. However, fungi are also responsible for human infections. The incidence of community-acquired and nosocomial fungal infections has increased considerably in recent decades. Antibiotic resistance development, the increasing number of immunodeficiency-and/or immunosuppression-related diseases and limited therapeutic options available are triggering the search for novel alternatives. These new antifungals should be less toxic for the host, with targeted or broader antimicrobial spectra (for diseases of known and unknown etiology, respectively) and modes of actions that limit the potential for the emergence of resistance among pathogenic fungi. Given these criteria, antimicrobial peptides with antifungal properties, i.e., antifungal peptides (AFPs), have emerged as powerful candidates due to their efficacy and high selectivity. In this review, we provide an overview of the bioactivity and classification of AFPs (natural and synthetic) as well as their mode of action and advantages over current antifungal drugs. Additionally, natural, heterologous and synthetic production of AFPs with a view to greater levels of exploitation is discussed. Finally, we evaluate the current and potential applications of these peptides, along with the future challenges relating to antifungal treatments.

show abstract

A novel covalent approach to bio-conjugate silver coated single walled carbon nanotubes with antimicrobial peptide

Cited by 48 publications

References 50 publications

Evaluation of E. coli inhibition by plain and polymer-coated silver nanoparticles

Evaluation of E. coli inhibition by plain and polymer-coated silver nanoparticles

Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo

Antifungal Peptides as Therapeutic Agents

Contact Info

Product

Resources

About